Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,  
Sector-18, Gurugram -122015, Haryana (India) 
 +91 124 4406710; 
 info@jagsonpal.com; 
 www.jagsonpal.com                    
Ph.:
E-mail:
Website:
L74899DL1978PLC009181
CIN :
. 
 
Regd. Office: Innov8 3
 Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)
,
rd
13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070
Mumbai Office: 
 
 
September 01, 2025 
 
The Department of Corporate Services- Listing 
BSE Ltd, 
Phiroze Jeejeebhoy Towers, 
Dalal Street 
Mumbai-400 001 
Scrip Code: 507789 
The Department of Corporate Services- Listing 
National Stock Exchange of India Ltd 
Exchange Plaza, C-1, Block G, 
Bandra Kurla Complex, 
Bandra (E) Mumbai – 400 051 
Symbol: JAGSNPHARM 
 
Subject: Business Responsibility and Sustainability Report for the financial year 2024-25 
 
Dear Sir/ Madam, 
 
Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 
2015, please find enclosed the Business Responsibility and Sustainability Report (“BRSR”) for the financial 
year 2024-25 which forms part of the Annual Report for the financial year 2024-25. 
 
We request you to take the above on record. 
  
Thanking you, 
 
For Jagsonpal Pharmaceuticals Limited 
 
 
 
Pratham Rawal 
Company Secretary & Compliance Officer 
 
Encl.: A/a 
 
 
 
JAGSONPAL PHARMACEUTICALS LIMITED 
UAGSONPAL! 
y -i 
akht 
A CSR Initiative 
PRATHAM 
RAWAL
Digitally signed by 
PRATHAM RAWAL 
Date: 2025.09.01 
16:39:59 +05'30'
77
Corporate Overview   |   Statutory Reports   |   Financial Statements
Business Responsibility and Sustainability Report
Section A: General Disclosures
I.	
Details of the listed entity
1.
Corporate Identity Number (CIN)
L74899DL1978PLC009181
2.
Name of company
Jagsonpal Pharmaceuticals Limited
3.
Year of incorporation
1978
4.
Registered office address
Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New 
Delhi- 110020
5.
Corporate office address
Plot No. 412-415, Nimai Tower, 3rd Floor, Phase -4, Udyog 
Vihar, Gurugram, Haryana- 122015
6.
E-mail
cs@jagsonpal.com
7.
Telephone
+91 124 4406710
8.
Website
www.jagsonpal.com
9.
Financial year for which reporting is being done
April 1, 2024 – March 31, 2025
10.
Name of the stock exchange(s) where shares are listed
BSE Limited and National Stock Exchange of India Limited
11.
Paid-up capital (In ₹)
₹ 13,27,97,260/-
12.
Name and contact details (telephone, email address) of 
the person who may be contacted in case of any queries 
on the BRSR report
Name: Mr. Pratham Rawal, Designation: Company 
Secretary, Telephone no.: +91 124 4406710
Email Id: cs@jagsonpal.com
13.
Reporting boundary
Standalone basis
14.
Name of assurance provider
NA
15.
Type of assurance obtained
NA
II.	
Products/services
16.	 Details of business activities (accounting for 90% of the turnover):
The company is engaged in the business of marketing and distribution of pharmaceutical formulations.
17.	 Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
S. 
No. Product/Service
NIC Code
% of total turnover contributed
1.
Pharmaceutical formulations
21002
97%
III.	 Operations
18.	 Number of locations where plants and/or operations/offices of the entity are situated:
•	
Registered Office in New Delhi
•	
Corporate Office in Gurugram, Haryana
•	
Branch Office in Mumbai, Maharashtra
•	
Warehouse in Ghaziabad, Uttar Pradesh
19.	 Markets served by the entity
	
(A)	 No. of locations
Locations
Number
National (No. of States)
28
International (No. of Countries)
2
(B)	 What is the contribution of exports as a percentage of the total turnover of the entity?
Exports – Exports contribute 1.3% of the total turnover of the company.
(C)	 A brief on types of customers?
Customers – The customers are important stakeholders in our business. The primary channels of distribution is 
through Stockist and Institutional Buyers.
78
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
IV.	 Employees
20.	 Details as at the end of Financial Year
 
a. 
Employees and workers (including differently abled):
Sr. 
No. Particulars
Total
Male
Female
(A)
No. (B)
% (B / A)
No. (C)
% (C / A)
EMPLOYEES
1
Permanent (D)
1399
1365
98%
34
2%
2
Other than Permanent (E)
6
4
67%
2
33%
3
Total employees (D + E)
1405
1369
98%
36
2%
WORKERS
4
Permanent (F)
-
-
-
-
-
5
Other than Permanent (G)
5
5
100%
-
-
6
Total employees (F + G)
5
5
100%
-
-
 
b. 
Differently abled Employees and workers:
S.
No. Particulars
Total
Male
Female
(A)
No. (B)
% (B / A)
No. (C)
% (C / A)
1.
Permanent (D)
0
0
0%
0
0%
2.
Other than Permanent (E)
0
0
0%
0
0%
3.
Total differently abled employees 
(D + E)
0
0
0%
0
0%
4.
Permanent (F)
0
0
0%
0
0%
5.
Other than
0
0
0%
0
0%
Permanent (G)
6.
Total differently abled workers 
(F + G)
0
0
0%
0
0%
21.	 Participation/Inclusion/Representation of women
Total (A)
No. and percentage of Females
No. (B)
% (B / A)
Board of Directors (including MD)
6
2
33%
Key Managerial Personnel (CFO and CS)
2
0
0%
22.	 Turnover Rate for Permanent Employees and Workers:
FY 2024-25 (Turnover rate in 
current FY) Resignations
FY 2023-24 (Turnover rate in 
previous FY) Resignations
FY 2022-23 (Turnover rate in 
the year Prior to the previous 
FY) Resignations
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
51%
1%
52%
58%
1%
59%
49%
1%
50%
Permanent Workers
-
-
-
-
-
-
-
-
-
V.	
Holding, Subsidiary and Associate Companies (including joint ventures)
23.	 (A) Names of holding/subsidiary/associate companies/joint ventures\
S. 
No.
Name of the holding/subsidiary/ 
associate companies/
joint ventures (A)
Indicate whether 
holding/ subsidiary/
associate/
joint venture
% of shares held 
by listed entity
Does the entity indicated at column 
A, participate in the Business 
Responsibility initiatives of the 
listed entity? (Yes/No)
As on March 31, 2025, Company does not have any Subsidiary, Associate or Joint Venture Company.
79
Corporate Overview   |   Statutory Reports   |   Financial Statements
VI.	 CSR Details
24.  i. 
Whether CSR is applicable as per Section 135 of Companies Act, 2013: Yes
 
ii. 
Turnover for FY 24-25 (in Millions) – `2687.16
 
iii. Net worth as on March 31, 2025 (in Millions) – `2399.50
 
VII. Transparency and Disclosures Compliances
25.	 Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible 
Business Conduct:
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanism in	Place 
(Yes/No)
(If	 Yes, then provide 
web-link for grievance 
redress policy)
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Communities
info@jagsonpal.com
0
0
NA
0
0
NA
Investors 
(other than 
shareholders)
cs@jagsonpal.com
0
0
NA
0
0
NA
Shareholders
cs@jagsonpal.com
7
1
Pending 
complaint 
has been 
resolved
4
0
NA
Employees and 
workers
info@jagsonpal.com
0
0
NA
0
0
NA
Customers
customercare@
jagsonpal.com
4
0
NA
8
0
NA
Consumers can raise 
a concern via post, via 
email (customercare@
jagsonpal.com) 
and reach out to us 
directly via telephone 
(+91-124 4406710). 
Also the consumer 
can reach out to the 
Company through 
official communication 
channel available on 
our website
www.jagsonpal.com
Value Chain 
Partners
-
-
-
-
-
-
-
Other (please 
specify)
-
0
0
NA
0
0
NA
80
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
26.	 Overview of the entity’s material responsible business conduct issues
The material issues are risks to the Company but at the same time, if acted upon proactively, could provide significant 
opportunities for the company over its competitors.
Some material issues identified are as follows –
ESG 
Dimension
Material issues
Indicate 
whether 
risk or 
opportunity
Management approach
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
Business 
Ethics
Prevention of 
bribery and 
corruption
Risk
The company is committed to preventing 
bribery and corruption. It fosters a transparent 
work environment where management and key 
personnel are readily accessible. To support 
this, policies such as the Whistleblower Policy 
have been implemented. Both External and 
Internal Stakeholders are encouraged to report 
any malpractices observed within the Company 
without any fear of retaliation.
Negative
Data 
protection
and 
Cybersecurity
Risk
The Company has a robust data protection and 
cybersecurity (EDR) system in place, including a 
cloud backup facility. It follows the 3-2-1 Data 
Protection and Recovery Plan, which involves 
maintaining three copies of server data on two 
different types of media, with one air-gapped 
copy stored offsite.
Negative
Human 
Resources
Occupational 
Health and 
Safety
Risk
The Company believes that a safe and healthy 
work environment for employees is essential to 
the growth of any organization. Furthermore, it 
has appropriate insurance coverage to manage 
any incidents of illness, injury or Fatalities. 
Employees are regularly updated on adopting 
safety measures within the office premises 
and reporting hazards, near-misses, and safety 
concerns, if any.
Negative
Training and 
Development
Opportunity
Employees are encouraged for in-house 
career development opportunities. Trainings, 
communications, and leadership development 
activities form the genesis of the organisation.
Negative
Supply Chain
Supply Chain 
Management
Risk
Jagsonpal has a network of suppliers and channel 
partners who are exposed to disruption risk. 
During the on-boarding activity for suppliers, 
channel partners and third-party contract 
manufacturers, detailed assessments are 
undertaken to ensure regulatory compliances.
Negative
Social 
outcomes
Product 
Quality
and Patient 
Safety
Risk
Jagsonpal understands its responsibility to 
provide its consumers with quality products. Our 
Quality teams proactively review complaints and 
work towards redressing them in an effective 
manner.
Negative
81
Corporate Overview   |   Statutory Reports   |   Financial Statements
Section B: Management and Process Disclosures
The section aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting 
the National Guidelines on Responsible Business Conduct (NGRBC) Principles and Core Elements. The NGRBC, as prescribed 
by the Ministry of Corporate Affairs, advocates nine principles referred as P1-P9 as given below:
a)	
Principle 1 (P1):	
Businesses should conduct and govern themselves with integrity and in a manner that is Ethical, 
Transparent and Accountable.
b)	
Principle 2 (P2):	
Businesses should provide goods and services in a manner that is sustainable and safe.
c)	
Principle 3 (P3):	
Businesses should respect and promote the well-being of all employees, including those in their 
value chains.
d)	
Principle 4 (P4):	
Businesses should respect the interests of and be responsive to all its stakeholders.
e)	
Principle 5 (P5):	
Businesses should respect and promote human rights.
f)	
Principle 6 (P6):	
Businesses should respect and make efforts to protect and restore the environment.
g)	
Principle 7 (P7):	
Businesses, when engaging in influencing public and regulatory policy, should do so in a manner 
that is responsible and transparent.
h)	
Principle 8 (P8):	
Businesses should promote inclusive growth and equitable development.
i)	
Principle 9 (P9):	
Businesses should engage with and provide value to their consumers in a responsible manner.
1.	
Principle-wise Policies and Procedures
Principle
Particulars
Policies
P1
Ethics and 
Transparency
The company has formulated the following policies to encourage an ethical 
and transparent culture within the organization and to express zero tolerance 
for unethical behaviour: Whistle blower Policy, Code of Conduct, Policy for 
Determination of Materiality of Events, Policy on Related Party Transactions, Code 
of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive 
Information, and Information Security Policy.
P2
Sustainable and Safe 
Product
The Company strives to achieve the goal of sustainability by balancing utilisation 
of its resources keeping in mind the social and environmental view along with 
economic perspective. We have established adequate procedures in place to 
ensure the delivery of high-quality products to our users.
P3
Well-being of 
Employees
The company recognizes human capital as an integral pillar and takes adequate 
steps to promote the individual goals of our human assets along with the 
company’s goals. Policies and procedures are put in place for employee welfare, 
guiding the organization to maintain a healthy work environment and systems for 
rewarding and recognizing deserving people.
P4
Responsive to 
Stakeholders
Company’s aims to create long term value for its stakeholders. It has defined 
proper procedures to protect and promote the interests of its internal as well as 
external stakeholders.
P5
Respect for Human 
Rights
We consider respecting human rights as our fundamental responsibility. It not only 
strengthens the trust of stakeholder in Company but also promotes a healthy and 
safe working environment for its employees facilitating efficient growth of the 
Company.
P6
Environment 
Protection
Promoting its goal of sustainability, the company strives to take adequate measures 
for energy conservation with efficiently employing technology. We take regular 
measures to create awareness among our employees in relation to promotion of 
sustainability.
P7
Public Policy 
Advocacy
The company has consistently focused on policies and advocated for changes to 
the existing policy frameworks whenever required.
P8
Inclusive Growth
Being part of society, it is our duty to give back for the benefit of society. To benefit 
society, we focus on education and livelihood, along with health and sanitation, as 
part of our CSR initiatives.
P9
Concern and Value 
for Customers
The Company acknowledges the role and importance of users of its products. We 
aim to deliver high standard products at affordable prices contributing to build 
a healthy nation. We have implemented procedures for redressal of consumer 
grievances and receipt of feedback Policies regarding Information Security and 
Cyber security ensure confidentiality of data and information available with the 
Company
82
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and management process
1.	
a.	
Whether your entity’s policy/policies cover each 
principle and its core elements of the NGRBCs. 
(Yes/No)
Y
Y
Y
Y
Y
Y
Y
Y
Y
	
b.	
Has the policy been approved by the board 
(Yes/No)
Yes, as applicable
	
c.	
Web Link of the policies, if available
https://www.jagsonpal.com/investor-relations
2.	
Whether the entity has translated the policy into 
procedure. (yes/No)
Yes (as applicable)
3.	
Do the enlisted policies extend to your value chain 
partners? (Yes/No)
Yes (as applicable)
4.	
Name of the national and International codes/ 
certifications/labels/standards (eg: SA 8000, OHSAS, 
IBO, BIS) adopted bu your entity with defined 
timelines, if any
All the contract manufacturing units, manufacturing drug 
products for Jagsonpal, comply with the national standards i.e. 
Schedule-M as per the Drugs and Cosmetics act 1940.
5.	
Specific commitments, goals and targets set by the 
entity with defined timelines, if any
This is not applicable since the company doesn’t operate any 
manufacturing facility thereby limiting the ability to set goals 
and targets for third parties.
6.	
Performance of the entity against the specific 
commitments, goals and targets along- with reasons 
in case the same are not met
Not Applicable
Governance, leadership and oversight
7.	
Statement by director responsible for the business 
Responsibility Report, highlighting ESG related 
challenges, targets and achievements (listed entity 
has flexibility regarding the placement of this 
disclosure)
The Company strongly believes that embedding 
Environmental, Social, and Governance (ESG) principles in its 
business operations is not only a responsible but an essential 
part of our business. Adherence to these principles helps build 
resilience, transform culture and long-term value creation to 
systematically identify opportunities, manage risk, and secure 
the interest of all our stakeholders.
8. 	
Details of the highest authority responsible for 
implementation and oversight of the business 
Responsibility policy (ies):
Director Identification Number (DIN): 06805265
Name: Mr. Manish Gupta
Designation: Managing Director
9. 	
Does the entity has a specified Committee of the 
Board/Director responsible for decision making on 
sustainability related issues? (Yes/No). If Yes, provide 
details.
Director Identification Number (DIN): 06805265
Name: Mr. Manish Gupta
Designation: Managing Director
10.	 Details of review of NGRBCs by the company
Subject for Review
Indicate whether review was 
undertaken by Director/
Committee of the board/any 
other committee (P1 to P9 )
Frequency (Annually/Half-
yearly/quarterly/any other-
please specify) (P1 to P9)
Performance against above policies and follow up 
action
The necessary adjustments 
to policies and procedures 
are implemented as required, 
and any instances of non-
compliance are noted for 
further appropriate action.
Policies of the Company are 
reviewed on a periodic basis to 
align it with regulatory changes
Compliance with statutory requirements of 
relevance to the principles, and rectification of any 
non-compliances
The company has no reportable 
non-compliances.
As and when necessary, in 
compliance with statutory 
requirements
11.	 Has the entity carried out independent 
assessment/ evaluation of the working of its 
policies by an external agency? (Yes/No). If yes, 
provide name of the agency.
No
12.	 If answer to question (1) above is “no” i.e., not all principles are covered by a policy reason to be stated.
Questions
P1 to P9
The entity does not consider the principles material to its business (Yes/No)
Not Applicable
The entity is not at a stage where it is in a position to formulate and implement the policies on 
specified principles (Yes/No)
The entity does not have the financial or/human and technical resources available for the task 
(Yes/No)
It is planned to be done in the next financial year (Yes/No)
Any other reason (please specify)
83
Corporate Overview   |   Statutory Reports   |   Financial Statements
Section-C: Principle – wise Performance Disclosure 
A.	 Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is 
Ethical, Transparent and Accountable.
The company has established a code of conduct to guide its ethical and transparent operations. Our defined organizational 
structure ensures clear accountability, reducing the risk of miscommunication.
We operate in the healthcare sector ensuring delivery of quality services at a reasonable price making it reachable for 
all sections of society. We endeavour to ensure compliance with all applicable laws, rules and regulations.
Essential Indicators
1.	
Percentage coverage by training and awareness programmes on any of the principles during the financial year:
All employees received training on how to conduct themselves as per their roles and responsibilities, during the Periodic 
Training, with 1185 Employees attending the Prevention of Sexual Harassment (POSH) training in 2024-25.
Segment
Total number of training And awareness programmes held and 
Topics principles covered under the training and its impact
% age of persons in respective 
category covered by the 
awareness programmes
Board of Directors 
& KMP
After appointment of directors, the company provides a 
comprehensive board induction Kit which captures company-
specific information at a board level. This is followed by 
management discussion. The Board of Directors submits a 
declaration for compliance with code of conduct on annual basis.
100%
Employees other 
than BOD and 
KMPs
Employees undergo various training programmes including 
prevention of sexual harassment, ethical business practices, 
prohibition of insider trading etc.
84%
Workers
Not applicable, since the company is not involved in 
Manufacturing
-
2.	
Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount  paid in proceedings 
(by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the 
financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as 
specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as 
disclosed on the entity’s website):
Monetary
NGRBC 
Principle
Name of the regulatory 
enforcement agencies/
judicial institutions
Amount (in `)
Brief of the case
Has an 
appeal been 
preferred? 
(yes/No)
Penalty/Fine
P1 – Ethics 
and 
Transparency
Office of the Principal 
Commissioner of 
Customs
5,09,79,206/-
Alleged incorrect 
classification of goods 
imported under 
Customs Act, 1962
Yes
Settlement
Nil
Nil
Nil
Nil
Nil
Compounding Fee
Nil
Nil
Nil
Nil
Nil
Non-Monetary
Imprisonment
Nil
Nil
Nil
Nil
Nil
Punishment
Nil
Nil
Nil
Nil
Nil
3.	
Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where 
monetary or non-monetary action has been appealed.
Case Details
Name of the regulatory/enforcement agencies/judicial 
institutions
Alleged incorrect classification of goods imported under 
Customs Act, 1962. Appeal has been preferred in this 
regard on May 27, 2025.
Customs Excise & service tax Appellate Tribunal
84
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
4.	
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, 
provide a web link to the policy.
The Company does not have any specific anti-corruption or anti-bribery policy, however the Company has code of 
conduct for its Directors, KMP’s and Senior Managerial Personnel. The Company’s employees also abide by the code of 
conduct, which prohibits corrupt and unfair practices.
The Company firmly believes that all the employees shall uphold the principles mentioned in the policy and fulfill their 
responsibilities with the utmost faith, discretion, and care, upholding the highest standards of honesty, integrity, and 
fairness. Companies Code of Conduct, Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive 
Information and policies like Whistle Blower Policy which are available at https://www.jagsonpal.com/investor-relations.
5.	
Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law 
enforcement agency for the charges of bribery/corruption.
There were no such instances for FY 2024-25 and 2023-24.
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Directors
Nil
Nil
KMPs
Nil
Nil
Employees
Nil
Nil
Workers
Nil
Nil
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Number
Remarks
Number
Remarks
Number of complaints received in relation to issues of conflict of 
interest of the directors
Nil
Nil
Nil
Nil
Number of complaints received in relation to issues of conflict of 
interest of the KMPs
Nil
Nil
Nil
Nil
7.	
Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken 
by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.
	
Not Applicable
8.	
Number of days of accounts payables ((Accounts payable *365)/ Cost of goods/services procured) in the 
following format:
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Number of days of accounts payables
37 Days
35 Days
9.	
Open-ness of business  
Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with 
loans and advances & investments, with related parties, in the following format: 
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Concentration of 
Purchases
a. Purchases from trading houses as % of total 
purchases
35.31%
18.69%
b. Number of trading houses where purchases 
are made from
35
23
c. Purchases from top 10 trading houses as % 
of total purchases from trading houses
79.39%
87.76%
Concentration of 
Sales
a. Sales to dealers/ distributors as % of total 
sales
80.37%
77.47%
b. Number of dealers/ distributors to whom 
sales are made
5701
2491
c. Sales to top 10 dealers/ distributors as % of 
total sales to dealers/ distributors
5.68%
8.69%
85
Corporate Overview   |   Statutory Reports   |   Financial Statements
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Share of RPTs in
a. Purchases (Purchases with related parties/ 
Total Purchases)
3.33%
7.69%
b. Sales (Sales to related parties/ Total Sales)
-
-
c. Loans & Advances (Loans & advances given 
to related parties/ Total loans & advances)
-
-
d. Investments (Investments in related parties/ 
Total Investments made)
-
-
Leadership Indicators
1.	
Awareness Programmes conducted for value chain partners on any of the Principles during the Financial Year.
The Company collaborates with partners who resonate with its core values. In case of any deviation or observed non- 
compliance in the operations of value chain partners, requisite corrective actions are taken.
2.	
Does the entity have Processes in place to avoid/manage conflict of interests involving members of the Board? 
(Yes/No) If yes, provide details of the same.
The Company’s code of conduct creates an awareness among Board of Directors in relation to conflict of interest 
and define procedures to avoid/manage any potential conflict of interest that may arise. In case of any such situation, 
company proactively take necessary steps to resolve the same before creation of any impact.
The Board of Directors also submits a declaration to the Company on an annual basis for compliance with Code 
of Conduct.
B.	 Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe.
As an organisation that prioritises the well-being of our patients, we are dedicated to delivering high-quality products 
that are safe for our users. We have put in place thorough procedures to ensure the quality of our products at every 
stage until they reach the consumers. Our product packaging for all our brands includes comprehensive details to 
ensure the safety of our consumers. We take proactive measures to identify and address any potential risks or issues 
associated with our products. Our procedures comply with Good Manufacturing Practice (GMP) regulations and other 
quality standards outlined in the JPL Quality Management System. By adhering to GMP, we consistently produce and 
maintain the highest quality standards for medicinal products.
Essential Indicators
1.	
Percentage of capital Expenditure (capex) Investments in specific technologies to improve the environmental 
and social impacts of product and processes to total capex investments made by the entity.
The Primary area of our operations lies in the marketing and distribution of pharmaceuticals. Hence, the above statement 
is relevant to us majorly in terms of information technology capital expenditure. No such capital expenditure has been 
incurred in FY 2025.
2. 
a. 
Does the entity have procedures in place for sustainable sourcing? (Yes/No)
Yes, the Company sources the finished formulation from leading contract manufactures who have implemented 
sustainable sourcing practices in-line with the global practices.
 
b. 
If Yes, what percentage of inputs were sourced sustainably?
100% of inputs sourced sustainably by our contract manufacturers.
3.	
Describe the processes in place to safely reclaim your products for reusing, recycling, and disposing at the end 
of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.
The Company has established procedures for the safe disposal of all the damaged and hazardous waste via incineration.
(a)	 Plastics (including packaging) - The company operates in pharmaceuticals industry where re-use and
recycling of pharmaceutical products is not involved.
(b)	 E-waste- The Company has established procedures for the safe disposal of waste via applicable practices.
(c)	 Hazardous waste - Since the Company is involved in marketing and distribution of pharmaceutical products,it has 
no exposure to generation of hazardous waste.
(d)	 Other waste - Apart from the things specified above, no other form of waste is produced by the Company.
9.	
Open-ness of business (Contd.)
86
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
4.	
Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If yes, 
whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to 
Pollution Control Boards? If not, provide steps taken to address the same Extended Producer Responsibility 
(EPR) is applicable to the entity’s activities.
Although the Extended Producer Responsibility (EPR) does not apply to our entity’s activities, we are dedicated towards 
environmentally sustainable waste management practices. In accordance with the guidelines set by the Central Pollution 
Control Board (CPCB), the company ensures the proper disposal of all types of waste. This includes expired and damaged 
goods, which are handed over to government-approved vendors for recycling or incineration, depending on the 
appropriate method. By adhering to these waste management processes, we prioritize responsible and eco-friendly 
practices in our operations.
Leadership Indicators
1.	
Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing 
industry) or for its services (for service industry)? If yes, provide details in the following format?
NIC Code
Name of 
Product/
Service
% of total Turnover 
contributed
Boundary for 
which the life 
cycle Perspective/ 
Assessment was 
conducted
Whether conducted 
by independent 
external agency
(Yes/No)
Results communicated 
in public domain.
(yes/No)
If yes, provide the web-
link
Not Applicable on us, since the Company is not involved in Manufacturing
2.	
If there are any significant social or environmental concerns and/or risks arising from production or disposal of 
your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other 
means, briefly describe the same along-with action taken to mitigate the same.
Name of Product/Service
Description of the risk/concern
Action Taken
Not Applicable on us, since the Company is not involved in Manufacturing
3.	
Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing 
industry) or providing services (for service industry).
Indicate input material
Recycled or re-used input material to total 
material
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Not Applicable on us, since the Company is not involved in Manufacturing
4.	
Of the products and packaging reclaimed at end-of-life of products, amount (in metric tonnes) reused, recycled, 
and safely disposed of
The company has established a process for facilitating the return of expired and damaged products to ensure their 
efficient disposal through authorized waste management agencies, specifically through incineration. We also obtain 
certificates as part of our quality control measures to certify the efficient disposal, ensuring that there is no possibility 
of expired or damaged products re-entering the market. This rigorous process minimizes potential risks to consumer 
health that may result from consuming expired or damaged products.
Quantum of expired and damaged goods sent for disposal:
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
Re-Used
Recycled
Safely Disposed
Re-used
Recycled
Safely Disposed
Plastics
-
-
Total Expired 
and Damaged 
goods sent for 
Disposal- 43070 
Kg
-
-
Total Expired 
and Damaged 
goods sent for 
Disposal- 25978 
Kg
(Including packaging)
E-waste
-
-
-
-
Hazardous
-
-
-
-
Other waste
-
-
-
-
5.	
Reclaimed products and their packaging materials (as percentage of products sold) for each product category.
Indicate product category
Reclaimed products and their packaging materials as % of 
total products sold in respective category
Not Applicable
Not Applicable
87
Corporate Overview   |   Statutory Reports   |   Financial Statements
C.	 Principle 3: Businesses should respect and promote the well-being of all employees, including those 
in their value chain.
We, at Jagsonpal strives to achieve simultaneously individual goals of our employees with organizational goals. We 
consider our employees as human capital. We have systems in place for adequate reward and recognition to the 
deserving employees which simultaneously acts an motivation for our employees to achieve better results.
Essential Indicators
1. 
(a) Details of measures for the well-being of employees
All employees are covered by well-being measures such as health and life insurances, accident insurance and 
maternity and other benefits (if applicable) as mentioned below:
Category
Health/Accident 
Insurance
Maternity benefits
Paternity Benefits
Day Care facilities
Number 
(B)
% (B / A)
Number 
(D)
% (D / A)
Number 
(E)
% (E / A)
Number 
(F)
% (F / A)
Permanent Employees
Male
1365
100%
-
-
1365
100%
1365
100%
Female
34
100%
34
100%
-
-
34
100%
Total
1399
34
1365
1399
Other than Permanent Employees
Male
4
100%
0
0%
0
0%
0
0%
Female
1
50%
0
0%
0
0%
0
0%
Total
5
-
-
-
-
-
-
 
(b) Details of measures for the well-being of workers:
Category
Health/Accident 
Insurance
Maternity benefits
Paternity Benefits
Day Care facilities
Number 
(B)
% (B / A)
Number 
(D)
% (D / A)
Number 
(E)
% (E / A)
Number 
(F)
% (F / A)
Permanent 
Workers
0
0%
0
0%
0
0%
0
0%
Other than 
Permanent 
Workers
5
100%
0
0%
0
0%
5
100%
Total
5
0
0
5
 
(c) 
Spending on measures towards well-being of employees and workers (including permanent and other than 
permanent) : 
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Cost incurred on well-being measures as a % of total revenue of 
the company 
0.23%
0.20%
2.	
Details of retirement benefits, for Current Financial Year and Previous Financial Year
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
No. of 
employees 
covered as a 
% of
total 
employees
No.	
of 
workers 
covered as a 
% of
total 
workers
Deducted 
and 
deposited 
with	
the
authority 
(Y/N/N.A.)
No. of 
employees 
covered as a 
% of
total 
employees
No.	
of
workers 
covered as a
% of total 
workers
Deducted 
and 
deposited 
with the 
authority 
(Y/N/N.A.)
PF
100
-
Y
100
-
Y
Gratuity
100
-
N
100
-
N
ESI
16
-
Y
17
-
Y
Others – please specify
-
-
-
-
-
-
88
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
3.	
Accessibility of workplaces
Are the premises/ offices of the entity accessible to differently abled employees and workers, as per the requirements 
of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.
Currently, the Company does not have any employee who is a differently-abled individual. Our Corporate office is 
situated in Gurugram, Haryana which is easily locatable and is equipped with necessary features to accommodate 
differently-abled employees. Our dedication towards promotion of well-being of our employees inspires us to go 
beyond compliance.
4.	
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, 
provide a web-link to the policy.
The Company believes in equality of opportunity for all persons irrespective of any disability. We recruit people basis 
their skills, knowledge ad overall behaviour. We strives to build a healthy workplace wherein no discrimination can be 
tolerated on the basis of disability, gender, etc. We have not formulated a separate equal opportunity policy, however, 
our human resource policies do not contain any separate provision for disabled person making him feel inferior to others 
and we fosters to grow together with all or human assets.
Whistle blower policy is available at: https://www.jagsonpal.com/investor-relations.
5.	
Return to work and Retention Rates of permanent Employees and Workers that took parental leave.
Gender
Permanent employees
Permanent workers
Return to work 
rate
Retention rate
Return to work 
rate
Retention rate
Male
100
100
-
-
Female
100
100
-
-
Total
100
100
-
-
6.	
Is there a mechanism available to receive and redress grievances for the employees and workers?
We strive to create a healthy and safe workplace for our employees wherein they can raise their concerns, provide 
suggestions on any matters. The Company consider their concerns or suggestions. Our whistle blower policy guides 
the employees for reporting their genuine concerns regarding any unethical behavior observed or suspected fraud or 
violation of company’s code of conduct. This policy contains provisions also with respect to protection of said person 
from victimization. Employees are encouraged to share their concerns with their reporting managers, the HR Department 
and members of the Senior Leadership Team.
The Company maintains a zero-tolerance stance on sexual harassment of women at the workplace and complies with 
the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, 
including the constitution of an Internal Complaints Committee (ICC).
The ICC is responsible for conducting inquiries into such complaints. Various training and awareness programmes have 
been conducted to sensitize employees on these matters. The Company remains committed to addressing all employee 
grievances in a fair and equitable manner.
Yes/No
(If yes, then give details of the mechanism in brief)
Permanent Workers
No
Other than Permanent Workers
No
Permanent Employees
Yes
Other than Permanent Employees
Yes
7.	
Membership of employees and workers in association(s) or Unions recognized by the listed entity:
The Company does not have any employee association(s) or Unions. Hence this parameter is not applicable.
89
Corporate Overview   |   Statutory Reports   |   Financial Statements
8.	
Details of training given to employees and workers
The various training courses conducted by Learning and Development function, throughout the year 2024-25, includes:
•	
Induction Training: 126 Induction Training Programs have been conducted for 713 newly inducted employees to 
cover job specific requirements.
•	
Refresher Training: 2 sessions of refresher training were conducted for 55 employees to reinforce their product 
knowledge and enhance their skills.
•	
Area Manager Orientation Program (AOP): 10 sessions conducted for 135 employees
•	
Skill Training for HO members: 3 sessions conducted for 67 employees.
•	
POSH: 60 Sessions on POSH have been conducted throughout the year, covering 1185 Participants
•	
In the year 2023-24: The following programmes were conducted
•	
Managerial Skill Development programmes: 5 sessions; 40 participants
•	
Induction & Refresher Training programmes: 69 programmes were conducted for 674 newly inducted employees 
to cover job specific requirements.
•	
Refresher Training of existing Employees: 27 sessions have been conducted for on Communication, De-tailing and 
In-Clinic Performance skills, and Objection Handling.
•	
POSH : 31 Sessions on POSH have been conducted throughout the year covering 781 Participants
9.	
Details of performance and career development reviews of employees and workers:
The Company has formulated criteria for reward and recognition to deserving candidates. We have implemented 
adequate measures for employees individual growth and development by conducting sessions periodically. Our 
performance cycle for employees is from April to March. The increment in remuneration for an employee depends on 
company’s growth coupled with his/her individual performance during the year.
Principle 3: 
Essential Indicators
Answer to Question No. 9: Details of Performance and Carrer Development reviews of employees and workers.
Category
FY 2024-25
 Current Financial Year
FY 2023-24
 Previous Financial Year
Total (A)
No. (B)
% (B/A)
Total (C)
No. (D)
% (D/C)
Employees
Male 
1399 
918 
67% 
1014
591
58%
Female
 6
 18
 50%
21
13
62%
Total
 1405
936 
 67%
1035
604
58%
Workers
Male
 5
0 
100% 
5
5
100%
Female
0
0
-
0
0
-
Total
5
5
100%
5
5
100%
10.	 Health and safety management system:
a.	
Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). 
If yes, what is the coverage of such a system?
The company is involved in the sale and distribution of pharmaceutical products. Since the company is not involved 
in manufacturing, its employees does not have any direct exposure to health and safety risks. However, the company 
is committed to protecting its employees from any issues that may arise in the normal course of business. The 
company complies with directives and guidelines issued by the government for the well-being of its employees. 
The company understands the importance of the physical and mental well-being of its employees and prioritises it.
90
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
b.	
What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis 
by the entity?
Company take action on regular basis to identify any work-related hazards for its employees and initiate process 
accordingly to mitigate such risks.
c.	
Whether you have processes for employees to report the work-related hazards and to remove themselves from 
such risks.
The Company endeavours to create an understanding among its employees about the potential safety risks that 
may probably arisen and are encouraged to highlight the same.
d.	
Do the employees/ workers of the entity have access to non-occupational medical and healthcare services?
The Company has undertaken a Group Mediclaim Policy, EDLI & Term Life Insurance and Group Accidental Insurance 
Policies for all of its employees, where Group Mediclaim Policy provides an option to employee to include their 
dependents in the same. Additionally, Company also conducts a full body health checkup of all the employees to 
ensure their overall well-being.
11.	 Details of safety-related incidents:
Safety Incident/Number
Category*
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Lost Time Injury Frequency 
Rate (LTIFR) (per	
one	
million-person
hours worked)
-
NIL
NIL
Total	recordable work-related 
injuries
25 road accidents were recorded 
in FY 2024-25 where employees, 
covered under Group Mediclaim & 
Accident Insurance policies were 
provided with monetary support 
for their hospitalisation and post 
discharge health support.
19 road accidents were recorded 
in FY 2023-24 where employees, 
covered under Group Mediclaim 
& Accident Insurance Policies were 
provided with monetary support 
for their Hospitalisation and post 
discharge health support.
No. of fatalities
1
1
High consequence work-
related injury or ill-health 
(excluding fatalities)
NIL
NIL
*including in the contract workforce
12.	 Describe the measures taken by the entity to ensure a safe and healthy workplace.
The Company endeavours to maintain a safe and healthy workplace for its employees both in terms of mental and 
physical health by implementing necessary measures in this regard. Additionally, we endeavour to remain compliant 
with guidance issued by concerned regulatory authorities in this regard.
a.	
Proper systems have been devised to ensure compliance with safety standards along with maintenance of proper 
hygiene in office premises.
b.	
Company has organised desk Yoga for our Gurugram Head office employees on International Yoga Day on June 
21, 2024.
13.	 Number of complaints on the following made by employees and workers.
Category
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
Filed 
during the 
year
Pending 
resolution 
at the end 
of year
Remarks
Filed 
during the 
year
Pending 
resolution 
at the end 
of year
Remarks
Working Conditions
Nil
Nil
Nil
Nil
Nil
Nil
Health & Safety
Nil
Nil
Nil
NIL
Nil
Nil
91
Corporate Overview   |   Statutory Reports   |   Financial Statements
14.	 Assessment for the Year:
Health and safety 
practices
Regular checks have been conducted to ensure the proper functioning of health and safety 
measures for employees.
Working Conditions
The Company aims to ensure excellent working conditions at its office premises and to comply 
with all relevant laws and regulations regarding fair working conditions and labor laws.
15.	 Provide details of any corrective actions taken or underway to address safety-related incidents (if any) and on 
significant risks / concerns arising from assessments of health and safety practices and working conditions.
The company is engaged in selling and distribution of products, hence this is not directly applicable basis nature of the 
business. However, the Company undertake necessary measures regularly, which have been covered in aforesaid points.
Leadership Indicators
1.	
 Does the entity extend any life insurance or any compensatory package in the event of death?
The company has implemented various employee benefit policies, including the EDLI Policy and Group Term Life 
Insurance Policy. These policies are prioritized in the event of an employee’s death.
2.	
Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited 
by the value chain partners.
Value chain partners are third parties, that’s why the Company does not deduct any statutory dues. The company 
reconciles its accounts and ensures that the amount deducted by Value chain Partners are reflected in our accounts as 
per IND AS- 26.
3.	
Provide the number of employees / workers having suffered high consequence work- related injury / ill-health 
/ fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable 
employment or whose family members have been placed in suitable employment.
Total no. of affected Employees/
Workers
No. of Employees/Workers that 
are rehabilitated and placed in 
suitable employment or whose 
family members have been 
placed in suitable employment
FY 2024-
25 (Current 
Financial Year)
FY 2023-24 
(Previous 
Financial Year)
FY 2024-
25 (Current 
financial Year)
FY 2023-24 
(Previous 
Financial Year)
Employees
0
0
0
0
Workers
0
0
0
0
4.	
Does the entity provide transition assistance programmes to facilitate continued employability and the 
management of career endings resulting from retirement or termination of employment? (Yes/ No)
We firmly believe in personal growth of our employees. Effective measures are taken by learning and development 
function to build new competencies, knowledge, and skills to help our employees upgrade their skills, grow and stay 
ahead of the curve which facilitates continuation of employment post-retirement or termination.
5.	
Details on assessment of value chain partners
We have efficient mechanisms in place to identify value chain partners. Proper measures are taken to identify risks 
associated in collaboration with such value chain partners and appropriate actions are taken to mitigate risks arising 
from such collaboration. We have a defined set of parameters for identification of risks.
6.	
Provide details of any corrective actions taken or underway to address significant risks/concerns arising from 
assessments of health and safety practices and working conditions of value chain partners.
Proper checking systems have been implemented to identify concerned risks arising from collaboration with value chain 
partners. The concentration level of risks pertaining to value chain partners are assessed on the basis of their established 
systems and processes. Appropriate mitigation strategies adopted to tackle such risks including health and safety.
In FY 2024-25: No case was found where corrective action was required.
In FY 2023-24: No case was found where corrective was required.
92
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders.
The company believes in upholding the interests of all stakeholders and aims to maximise their value. It recognises the 
importance of stakeholders in fostering success. The Company remains committed to earn the trust and support of its 
stakeholders by providing quality services.
Essential Indicators
1.	
Describe the processes for identifying key stakeholder groups of the entity.
The Company stakeholders as a cornerstone of the success of our business. We set certain guidelines and set of principles 
for our stakeholders. Being operated in the pharmaceutical industry, our patients are one of our key stakeholders. We 
strives to meet expectations of our stakeholders which enables us to earn our stakeholder’s confidence in us. We engage 
with our stakeholders on a periodic basis to obtain their feedback.
2.	
List of stakeholder groups identified as key for the entity and the frequency of engagement with each 
stakeholder group.
Stakeholder 
Group
Channels of communication (Email, SMS, 
Newspaper, Pamphlets, Advertisement, 
Community Meetings, Notice Board, 
Website), Other
Frequency of
engagement
Purpose and scope of engagement including 
key topics and concerns raised during such 
engagement
Patients and 
consumers
Webinars, Social media pages, Posters, 
Standees, Pamphlets
Ongoing and 
need based
Disease 
awareness 
programmes 
are 
organised to educate the general public 
about the signs, symptoms and diagnosis, 
treatment and prevention options for a 
disease to foster better patient outcomes 
through prevention, early diagnosis and 
management to minimise or slow disease 
progression and complications.
Healthcare 
Professionals 
(HCPs)
Face to face meetings, Emails, Webinars, 
Social media pages, Posters, Standees, 
Pamphlets, Doctor networking 
platforms, SMSs, Instant platforms etc.
Ongoing and 
need based
Keep the HCP abreast with the latest 
information on disease, science of our 
product and disease management through 
our product.
To provide avenues for HCPs to discuss and 
deliberate on latest data, clinical challenges 
and multidisciplinary expert discussions 
intending to help in improving treatment 
outcomes for the patients.
We ensure responsible sales and marketing 
practices, in compliance with local laws and 
applicable industry codes, while interacting 
with HCPs.
Investors and 
Shareholders
Annual General Meetings, Emails, 
Newspaper/ press release, 
Advertisement, Notices, Website, 
intimation to stock exchanges, 
annual/ quarterly financials and 
investor presentation / investor call  
/ participation in selected  investor 
conferences, annual reports
At least 
quarterly and 
need based
To stay abreast of developments in the 
Company, Performance of the Company and 
address concerns/grievances
Communities 
and NGOS
Emails, physical meetings, website and 
other digital platforms.
Need based
Implementing and monitoring the CSR 
activities
Government 
and Drug 
Regulators
Emails, Submissions through online 
Regulatory Agency portals or direct 
submissions to Regulatory Agency 
office
Policy 
and 
Regulatory 
Matters, 
Grant 
and maintenance of licenses pertaining 
to manufacturing and marketing of our 
products, pricing of medicines and other 
regulatory approvals
Suppliers and 
Distributors
Emails, physical meetings, website and 
other digital platforms
Ongoing and 
need based
Quality of material, commercial and technical 
terms of payment and delivery, compliance 
to our ethics, ways of working and statutory 
requirements
Employees
Direct, email, town halls, team 
meetings.
Ongoing and 
need based
Performance appraisal, training and career 
development, wellness and safety measures, 
rewards and recognitions
93
Corporate Overview   |   Statutory Reports   |   Financial Statements
Leadership Indicators
1.	
Provide the processes for consultation between stakeholders and the Board on economic, environmental, and 
social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.
Refer answer to Question 2 of essential indicators
2.	
Whether stakeholder consultation is used to support the identification and management of environmental, 
and so-cial topics (Yes / No). If so, provide details of instances as to how the input received from stakeholders 
on these top-ics were incorporated into policies and activities of the entity.
Refer answer to Question 2 of essential indicators
3.	
Details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalised 
stakeholder groups.
Being a part of society and a good corporate citizen, the company recognizes its duty to create a positive impact on 
society specially on weaker sections of the society. The Company’s CSR initiatives primarily focus on two core areas:
•	
Education and Livelihood
•	
Health and Sanitation
Company has constituted a CSR Committee in terms of applicable provisions of the Companies Act, 2013 which review 
the progress in CSR initiatives on regular basis. Through its ongoing projects, company is focusing on the following areas:
•	
Promotion of Menstruation Hygiene
•	
Environmental Cleanliness
In pursuance of its CSR initiatives, Company has launched a website named “My Sakhi” focusing specifically on the topic 
of Menopause. The Company has also built toilets, in collaboration with Sulabh International Social Service Organization, 
with emphasis around women schools and public places.
Principle 5: Businesses should respect and promote human rights.
We recognise the importance of fundamental human rights and is dedicated to protect them. It prohibits any act or omission 
that violates an individual’s human rights. The Company continuously strives to create a wholesome and secure work 
atmosphere for its employees, free from any kind of discrimination. To protect the dignity and human rights of its employees, 
the Company has formulated various policies, including the Prevention of Sexual Harassment Policy, Whistleblower Policy, 
and Code of Conduct.
Essential Indicators
1.	
Employees and workers who have been provided training on human rights issues and policies of the entity.
Our employees have been given training for professional development that focus on enhancing employees’ professional 
skills, behaviour, and conduct in the workplace. Apart from professional development, employees are trained on 
prevention of sexual harassment as well to sensitise them towards gender diversity. 1185 Employees attended POSH 
training in 2024-25.
Category
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
Total (A)
No. of 
employees 
/ workers 
covered 
(B)
% (B / A)
Total (C)
No. of 
employees 
/ workers 
covered 
(D)
% (D / C)
Employees
Permanent
1399
964
69%
1025
776
76%
Other than permanent
6
6
100
10
5
50%
Total Employees
1405
970
69%
1035
781
75%
Workers
Permanent
0
-
0
-
-
Other than permanent
5
-
5
-
-
Total Workers
5
-
5
-
-
94
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
2.	
Details of minimum wages paid to employees and workers:
Category
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
Total 
(A)
Equal to
Minimum Wage
More than
Minimum Wage
Total (D)
Equal to
Minimum Wage
More than
Minimum Wage
No.(B)
% (B / 
A)
No. (C)
% (C / 
A)
No. (E)
% (E / 
D)
No. (F)
% (F / 
D)
Employees
Permanent
Male
1365
-
-
1365
100%
1005
-
-
1005
100%
Female
34
-
-
34
100%
20
-
-
20
100%
Other Permanent than
Male
4
-
-
4
100%
9
-
-
9
100%
Female
2
-
-
2
100%
1
-
-
1
100%
Workers
Permanent
Male
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
Other Permanent than
Male
5
-
-
-
100%
5
-
-
5
100%
Female
-
-
-
-
-
-
-
-
-
-
3.	
Details of remuneration/salary/wages
 
a. 
Median remuneration/ wages:
Male
Female
Number
Median remuneration/ 
salary/ wages of 
respective category
Number
Median remuneration/ 
salary/ wages of 
respective category
Board of Directors (BoD)
4
29.07
2
-
Key Managerial Personnel
3
5.63
0
-
Employees other than BoD and KMP
1370
0.35
36
0.45
Workers
5
0.26
-
Other
0
0
0
0
 
b. 
Gross wages paid to females as % of total wages paid by the entity:
FY 2024-25 
Current Financial Year
FY 2023-24 
Previous Financial Year
Gross wages paid to females as % of total wages 
2.7%
2.2%
4.	
Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues 
caused or contributed to by the business? (Yes/No)
At Jagsonpal, Mr. Bharat Chugh, General Manager, Human Resource is responsible to ensure effective resolution of any 
matter related to human rights caused by the business.
5.	
Describe the internal mechanisms in place to redress grievances related to human rights issues
Any matter which is unethical or is in violation of human rights of any individual can be reported to the General Manager, 
Human Resources, who proactively addresses the matter and undertakes suitable action to resolve the same. We have 
constituted an internal committee under policies like Prevention of Sexual Harassment of Women at workplace, Whistle 
blower, Grievance Redressal, etc which is solely responsible to address and resolve matters of violation.
6.	
Number of Complaints on the following made by employees and workers:
We have not received any complaint regarding child labour, forced labour, wages, sexual harassment and discrimination 
at workplace in the current or previous financial year.
95
Corporate Overview   |   Statutory Reports   |   Financial Statements
Category
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
Filled 
during the 
year
Pending 
resolution 
at the end 
of the year
Remarks
Filed 
during the 
year
Pending 
resolution 
during the 
year
Remarks
Sex
ual Harassment
0
0
NA
0
0
NA
Discrimination at workplace
0
0
NA
0
0
NA
Child Labour
0
0
NA
0
0
NA
Forced Labour/Involuntary Labour
0
0
NA
0
0
NA
Wages
0
0
NA
0
0
NA
Other human rights related issues
0
0
NA
0
0
NA
7.	
Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) 
Act, 2013:
FY 2024-25
FY 2023-24
Total Complaints reported under Sexual Harassment of Women at 
Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)
0
0
Complaints on POSH as % of female employees/ workers
0
0
Complaints on POSH upheld
0
0
8.	
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.
The company has established effective mechanisms to prevent victimization of individuals in cases of discrimination and 
harassment. We have an internal committee to address cases under the Prevention, Prohibition, and Redressal of Sexual 
Harassment of Women at Workplace Act of 2013. This committee is authorized to take disciplinary action, including 
dismissal, against any person who threatens or takes revenge against a complainant. Our company has a zero-tolerance 
policy for such behaviour.
9.	
Do human rights requirements form part of your business agreements and contracts? (Yes/No)
The Company aims to operate ethically in a transparent manner. We emphasis the importance of human rights in our 
core values. We enter into deal with only such parties who meets with our criteria regarding compliance of human right 
matters. Preliminary evaluation activity has been conducted before entering into any agreement and contract to check 
the core values of counter party. We prevent engagement in unethical practices violating human rights such as child 
labour, forced labour, minimum wages, working hours, etc.
10.	 Assessments of the year
Our mechanisms for such kind of matters has been internally reviewed by the Company to reduce the risk of non-
compliances and no such non-compliances has been observed.
% of your plants and offices that were assessed
(By entity or statutory authorities or third parties)
Child Labour
Nil
Forced/Involuntary Labour
Nil
Sexual Harassment
Nil
Discrimination at Workplace
Nil
Wages
Nil
Other-please specify
Nil
11.	 Provide details of any corrective actions taken or underway to address significant risks / concerns arising 
from the assessments at Question 10 above.
Not Applicable since there were no cases recorded for the significant risks/concerns mentioned at Question 10 during 
the year under review.
96
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
Leadership Indicators
1.	
Details of a business process being modified/introduced because of addressing human rights grievances/
complaints.
During the year under review there were no instances of human rights violation recorded and no complaints were lodged. 
Accordingly, requirement of modification/introduction of a business process didn’t arise.
2.	
Details of the scope and coverage of any Human rights due diligence conducted.
The Company respects human rights and is dedicated to the protection of the same. It discourages any kind of activity 
that violates human rights in any way, for example, child labour, forced labour, human trafficking, discrimination, etc. 
The Company has zero tolerance against any act that is violative of human rights.
3.	
Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the 
Rights of Persons with Disabilities Act, 2016?
Our corporate office is situated in Gurugram, Haryana, and is easily locatable and accessible to differently abled visitors 
and is equipped with necessary infrastructural requirements for differently abled visitors.
4.	
Details on assessment of value chain partners:
As part of the Company’s on-boarding process, all third-party vendors, suppliers, and contract manufacturers, are 
evaluated regarding compliance on human rights matters like child labour, forced labour, non-discriminatory, safe and 
healthy workplace, minimum wages, working hours etc. Upon satisfactory assessment of their policies and procedures 
on said matters, they are engaged subject to their assurance and commitment towards Jagsonpal’s value system.
% of Value chain partner
(By value of business done with such partners) that 
were assessed
Child Labour
Nil
Forced/Involuntary Labour
Nil
Sexual Harassment
Nil
Discrimination at Workplace
Nil
Wages
Nil
Other-please specify
Nil
5.	
Provide details of any corrective actions taken or underway to address significant risks / concerns arising 
from the assessments at Question 4 above.
There was no requirement to implement ant corrective measures as no significant risks/concerns has been arisen from 
assessment of value chain partners as mentioned as answer to Question 4 above.
Principle 6: Businesses should respect and make efforts to protect and restore the environment.
The Company acknowledges its responsibility to safeguard the environment. It is enhancing its systems and procedures by 
adopting a technology-driven approach and reducing its reliance on practices that negatively impact the environment. The 
Company is committed to minimising its environmental footprint and contributing to environmental restoration. Additionally, 
it has implemented efficient waste management initiatives and established a system for disposing of damaged and expired 
goods through incineration.
Essential Indicators
1.	
Details of Total energy consumption (in Joules or multiples) and energy intensity:
(Note: below data is for Corporate Office and warehouse)
116308.2 Units (kwh/kvah) has been total electricity consumption at Corporate Office and warehouse.
97
Corporate Overview   |   Statutory Reports   |   Financial Statements
2.	
Does the entity have any sites/facilities identified as designated consumers (DCs) under the Performance, 
Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under 
the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, 
if any.
The company does not have any sites or facilities identified as designated consumers (DCs) under the Perform, Achieve, 
and Trade (PAT) Scheme of the Government of India.
3.	
Provide details of the following disclosures related to water:
The Company recognises the significance of water for human survival and commits to minimize its wastage in each 
possible manner. Since the company is engaged only in selling and distribution of pharmaceutical products, our usage 
of water is limited to human consumption at our corporate office. We commit to use the water in a prudent manner. We 
remain focused on sustainable use of water.
4.	
Provide the following related to water discharged:
The company is not involved in the manufacturing of any product and hence, parameters related to discharge of water 
is not applicable on us.
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) 
If yes, name of the external agency.
5.	
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
implementation.
The company’s usage of water is limited to human consumption as it does not have a manufacturing plant. The company 
encourage its employees to use water in a sustainable manner reducing its wastage.
6.	
Please provide details of air emissions (other than GHG emissions) by the entity:
This parameter is not applicable since the company is not operating any manufacturing plant. 
7.	
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) and its intensity:
Not applicable since the company is not operating any manufacturing plant. 
8.	
Does the entity have any project related to reducing Greenhouse Gas emissions? If Yes, then provide details.
Not applicable since the company is not operating any manufacturing plant.
9.	
Provide details related to waste management by the entity:
The company has established a system for effective waste disposal through waste Management Agencies. Because 
the company sells and distributes pharmaceutical products, there is a significant risk of product expiration. Therefore, 
products that are near expiry, expired, or damaged are considered as waste. Once identified, they are handed over to 
a Government CPCB authorised waste management agencies for efficient disposal by way of incineration. Certificates 
are obtained to ensure proper waste disposal, preventing the return of such products to the market and preserving 
consumer and environmental health.
Quantum of expired goods and damaged goods sent for disposal:
FY 2023-24: 25978 Kg (25.978 MT)
FY 2024-25: 43070 Kg (43.070 MT)
98
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
Parameter
FY 2024-25
(Current Financial Year)
FY 2023-24
(Previous Financial 
Year)
Total waste generated (in metric tonnes)
Plastic waste (A)
NA
0
E-waste (B)
NA
NA
Bio-medical waste (C)
NA
NA
Construction and demolition waste (D)
NA
0
Battery waste (E)
NA
0
Radioactive waste (F)
NA
NA
Other Hazardous waste. Please specify, if any. (G)
43.070
25.978
Other Non-hazardous waste generated (H). Please Specify, if any.
NA
0
(Break-up by composition i.e., by materials relevant to the sector)
Total (A+B+C+D+E+F+G+H)
43.070
25.978
Waste intensity per rupee of turnover 
(Total waste generated/ Revenue from Operations)
NA
NA
Waste intensity per rupee of turnover adjusted for Purchasing 
Power Parity (PPP)
(Total waste generated/ Revenue from operations adjusted for PPP)
NA
NA
Waste intensity in terms of physical output
NA
NA
Waste intensity (optional)- the relevant metric may be selected by 
the entity
NA
NA
For each category of waste generated, total waste recovered 
through recycling, re-using or other recovery operations (in 
metric tonnes)
Category of waste
(i)	
Recycled
0
0
(ii)	
Re-used
(iii)	 Other recovery operations
Total
0
0
For each category of waste generated, total waste disposed by 
nature of disposal method.
(in metric tons)
Category of Waste
(i)	
Incineration
43.070
25.978
(ii)	
Landfilling
0
0
(iii)	 Other disposal operations
0
0
Total
43.070
25.978
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) 
If yes, name of the external agency.
99
Corporate Overview   |   Statutory Reports   |   Financial Statements
10.	 Briefly describe the waste management practices adopted in your establishments. Describe the strategy 
adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes 
and the practices adopted to manage such wastes.
This point is directly not applicable to the Company as it does not operate a manufacturing plant. The company 
outsources its product manufacturing through contract manufacturing arrangements. We get third plant manufacturing 
audited at regular intervals by our quality assurance department, to ensure its compliance with Central Pollution Control 
Board/State Pollution Control Board guidelines, and Hazardous and other waste (Management and Transboundary) 
Rules 2016.
11.	 If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife 
sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where 
environmental approvals/clearances are required:
This parameter is not applicable on the Company as it does not have any offices in ecologically sensitive areas.
12.	 Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in 
the current financial year:
Basis notification of the Ministry of Environment, Forests and Climate Change (MOEFCC) in India, an Environmental 
Impact Assessment (EIA) required to be carried out for those industries which impact environment negatively. The 
Company is not required to perform an EIA pre-clearance by the MOEFCC as it is into marketing and distribution of 
pharmaceuticals and does not have any operations which could have any adverse impact on the environment.
Name and 
brief details of 
project
EIA 
Notification 
No.
Date
Whether conducted by 
Independent external 
agency (Yes/No)
Results communicated in public 
domain. (Yes/No)
Relevant Web 
Link
Not Applicable
13.	 Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the 
Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment 
protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following 
format:
The Company remains compliant with the requisite environmental law/regulations/guidelines in India and there are no 
non-compliances reported for FY 2024-25.
S. 
No.
Specify the law/ regulation/ 
guidelines which was not 
complied with
Provide details of the non-
compliance
Any fines / penalties/ action taken by 
regulatory agencies such as pollution 
control boards or by courts
Corrective 
action taken 
if any
Nil
Nil
Nil
Nil
Leadership Indicators
1.	
Water withdrawal, consumption and discharge in areas of water stress (in kiloliters):
Since the company is not engaged in manufacturing. It is not applicable on the company
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) 
If yes, name of the external agency. 
Not Applicable since the company is not engaged in manufacturing. 
2.	
Please provide details of total Scope 3 emissions & its intensity, in the following format:
Since the company is not engaged in manufacturing, It is not applicable on the company.
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) 
If yes, name of the external agency.
Not Applicable since the company is not engaged in manufacturing.
3.	
With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide 
details of significant direct and indirect impact of the entity on biodiversity in such areas along-with prevention 
and remediation activities.
Not applicable as the Company does not have operations in ecologically sensitive areas.
100
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
4.	
If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve 
resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide 
details of the same as well as outcome of such initiatives:
The Company’s carbon footprint is restricted to the use of consumables such as paper, plastic, water and energy as 
Company operates in marketing and distribution of pharmaceuticals and does not have its own manufacturing units.
Sr. No
Initiative undertaken
Details of the initiative (Web-link, if any, may be 
provided along-with summary)
Outcome of the initiative
Not Applicable
5.	
Does the entity have a business continuity and disaster management plan?
The Company has formulated a business continuity plan to be implemented in case of any exigencies. 
6.	
Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What 
mitigation or adaptation measures have been taken by the entity in this regard?
The company does not operate a Manufacturing unit, it has no adverse impact on the environment. However, company 
endeavours to minimise its impact on environment caused due to using plastic, paper, etc.
7.	
Percentage of value chain partners (by value of business done with such partners) that were assessed for 
environmental impacts.
The contract manufacturers and suppliers are assessed at the time of onboarding and periodically thereafter for 
compliance with Good Manufacturing Practices (GMP). It is also ensured that their standard operating procedures are 
aligned with the Company’s Quality Management System (QMS) through regular audits of contract manufacturing 
sites. Consequently, GMP, along with the company’s QMS, ensures the mitigation of environmental risks in this regard.
Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a 
manner that is responsible and transparent.
Essential Indicators
1. 
a. 
Number of affiliations with trade and industry chambers/ associations.
The Company is not a member of any trade and industry associations.
 
b. 
List the top 10 trade and industry chambers/ associations (determined based on the total members of such a 
body) the entity is a member of/ affiliated to.
S. 
No.
Name of the trade and industry chambers/ 
associations
Reach of trade and industry chambers/ associations
(State/National)
1.
NA
NA
This list of top 10 trades and industry associations is not applicable on the Company as Company is not a member of 
any trade and industry associations.
2.	
Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the 
entity, based on adverse orders from regulatory authorities.
There were no material instances reported or any orders received from regulatory authorities on any issues related to 
anti-competitive conduct by the entity.
Leadership Indicators
1.	
Details of public policy positions advocated by the entity:
Sr. No.
Public policy 
advocated
Method 
resorted for 
such advocacy
Whether information 
available in public domain 
(Yes/No)
Frequency of review by Board
(Annually/Half yearly/ quarterly/ 
Others – please specify)
Web Link, if 
available
Nil
Principle 8: Businesses should promote inclusive growth and equitable development
The Company firmly believes in promoting inclusive growth and equitable development. It aims to provide quality services at 
a reasonable cost, without any discrimination based on gender, caste, religion, background, etc. The Company has identified 
Health and Sanitation, as well as Education and Livelihood, as core areas for its CSR initiatives, which are designed to uplift 
marginalised communities.
101
Corporate Overview   |   Statutory Reports   |   Financial Statements
Essential Indicators
1.	
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in 
the current financial year.
During the year under review, the Company has not undertaken Social Impact Assessment of any projects.
Name and 
brief details of 
project
SIA 
Notification 
No.
Date of 
notification
Whether conducted by 
independent external 
agency (Yes/No)
Results communicated in Public 
domain
(Yes/No)
Relevant Web 
link
NA
2.	
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R & R) is being 
undertaken by your entity.
We operate in selling and distribution of pharmaceutical products, hence our operations does not resulted into 
community displacement. Therefore, requirement for Rehabilitation and Resettlement (R&R) does not arise.
Sr. 
No.
Name of the project for 
which R&R is ongoing
State
District
No. of projects affected 
Families (PAFs)
% of PAFs covered 
by R&R
Amounts paid to PAFs 
in the FY (In `)
NA
3.	
Describe the mechanisms to receive and redress the grievances of the community.
Not Applicable
4.	
Percentage of input material (inputs to total inputs by value) sourced from supplier.
Not Applicable
FY 2024-25
(Current Financial Year)
FY 2023-24
(Previous Financial Year)
Directly sourced from MSMEs/ small producers
0
0
Directly from within India
0
0
5.	
Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers 
employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total 
wage cost.
Location
FY 2024-25
(Current Financial Year)
FY 2023-24
(Previous Financial Year)
Rural
4.72%
0.53%
Semi-urban
1.24%
1.99%
Urban
42.27%
40.87%
Metropolitan
51.78%
57%
(Place to be categorized as per RBI Classification System – rural/ semi-urban/ urban/ metropolitan)
Leadership Indicators
1.	
Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact 
Assessments
(Reference: Question 1 of Essential Indicators above):
Details of negative social impact identified
Corrective action taken
Nil
Nil
2.	
Provide the following information on CSR projects undertaken by your entity in designated aspirational 
districts as identified by government bodies:
Not Applicable
102
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
3.	
(a)	
Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising 
marginalized /vulnerable groups? (Yes/No) - No
	
(b)	 From which marginalized /vulnerable groups do you procure? - Not Applicable
	
(c)	
What percentage of total procurement (by value) does it constitute? - Not Applicable
4.	
Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity 
(in the current financial year), based on traditional knowledge:
Sr. 
No.
Intellectual Property based on 
traditional knowledge
Owned/Acquired
(Yes/No)
Benefit Shared
(Yes/No)
Basis of calculating 
benefit share
Nil
5.	
Details of corrective actions taken or underway, based on any adverse order in intellectual property related 
disputes wherein usage of traditional knowledge is involved.
Name of Authority
Brief of the case
Corrective action taken
Nil
6.	
Details of beneficiaries of CSR Projects:
To improve women’s hygiene and sanitation facilities, we have constructed four girls’ toilets at various locations in 
Uttarakhand and Punjab as part of our CSR initiatives. This aligns with our commitment to health and sanitation, 
benefiting approximately 2330 people.
Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner
The Company strives to provide quality services with a prime focus on women’s health. It has implemented necessary 
procedures to ensure the delivery of safe and healthy products to consumers by ensuring compliance with Good Manufacturing 
Practices (GMP) by partnered contract manufacturers.
Essential Indicators
1.	
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
The Company has implemented efficient measures to address consumer complaints and feedback. It endeavours to 
resolve consumer complaints proactively and consider their valuable feedback to improve systems. Consumers can 
submit their complaints and feedback via email at info@jagsonpal.com; customercare@jagsonpal.com; Lycored@
jagsonpal.com as mentioned on the pack of products or call us at 0124-4406710 or send us the written complaint at 
our Corporate Office situated at Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Sector – 18, Gurugram 
-122015, Haryana (India)
2.	
Turnover of products / services as a percentage of turnover from all products/services that carry information 
about:
Particulars
As a percentage to the total turnover
Environmental and social parameters 
relevant to the product
Not applicable
Safe and responsible usage
100%
Recycling and/or safe disposal
Not applicable - While the Company does not specifically mention any such 
details on its products, it complies with all statutory requirements of the 
Pollution Control Boards etc.
3.	
Consumer complaints in respect of Data Privacy, Advertising, Cyber-Security, Delivery of Essential Services, 
Restrictive and Unfair Trade Practices.
No consumer complaints with respect to the aforesaid were received during FY 2024-25.
103
Corporate Overview   |   Statutory Reports   |   Financial Statements
Category
FY 2024-25
Current Financial Year
FY 2023-24
Previous Financial Year
Received 
during the 
year
Pending 
resolution 
at end of 
year
Remarks
Received 
during the 
year
Pending 
resolution 
at end of 
year
Remarks
Data Privacy
Nil
Nil
NA
Nil
Nil
NA
Advertising
Nil
Nil
NA
Nil
Nil
NA
Cyber- security
Nil
Nil
NA
Nil
Nil
NA
Delivery of essential services 
Nil
Nil
NA
Nil
Nil
NA
Restrictive trade practices
Nil
Nil
NA
Nil
Nil
NA
Unfair trade practices
Nil
Nil
NA
Nil
Nil
NA
Other
Nil
Nil
NA
Nil
Nil
NA
4.	
Details of instances of product recalls on account of safety issues:
No product recalls have been made during FY 24-25.
Number
Reason for recall
Voluntary recalls 
Nil
Nil
Forced recalls 
Nil
Nil
5.	
Does the entity have a framework/policy on cyber security and risks related to data privacy? (Yes/No) If 
available, provide a web-link of the policy.
The Company has a world-class firewall and antivirus installed on its network. The Company has complete data protection 
and cloud backup solutions (EDR) Systems which are continuously being monitored by professionals to avoid data 
breaches and hacking threats. There exists 3-2-1 Data Protection and Recovery Plan; three copies of server data, two 
different types of media, and one air-gapped copy located offsite. The IT department is the custodian of policy on cyber 
security and risks related to data privacy.
6.	
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of 
essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; 
penalty / action taken by regulatory authorities on safety of products / services.
During the year under review, all the complaints received from consumers were related to packaging of the products and 
there were no instances recorded for any issue in relation to cyber security and data privacy of customers; re-occurrence 
of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.
7.	
Provide the following information relating to data breaches:
a.	
Number of instances of data breaches – Nil
b.	
Percentage of data breaches involving personally identifiable information of customers - NA
c.	
Impact, if any, of the data breaches - NA
Leadership Indicators
1.	
Channels / platforms where information on products and services of the entity can be accessed (provide web 
link, if available).
The information regarding the company’s products and services can be accessed at https://www.jagsonpal.com/.
2.	
Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.
Steps Taken to Inform and Educate Consumers about Safe and Responsible Usage of Products and Services
a.	
Equipping Sales Representatives: Sales representatives are provided with visual aids to effectively disseminate 
information to Healthcare Professionals (HCPs).
b.	
Educational Sessions: The Company conducts sessions on the responsible usage of its medicines with HCPs 
through webinars and conferences. These sessions update HCPs on the science behind the medicines during 
Continuing Medical Education (CME) activities and webinars.
c.	
Dosage Instructions: Physicians direct the dosage instructions for prescriptive drugs based on their examination 
of patients. Product packaging clearly includes directives for usage under the guidance of a medical practitioner.
104
Jagsonpal Pharmaceuticals Limited | Annual Report 2024-25
d.	
Comprehensive Product Information: Medical representatives use product information leaflets that include the 
generic name, composition, dosage form and strength, clinical particulars (e.g., therapeutic indication, method of 
administration), contraindications, special warnings and precautions on use, and overdose information.
e.	
Patient Education Materials: Posters and related materials are created for patient education in easy-to-understand 
language. These materials are also available in regional languages to ensure broader accessibility and understanding
3.	
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
Keeping consumers informed about disruptions or discontinuations of essential services is crucial. Jagsonpal employs 
these methods to keep consumers informed. In addition to providing public announcements through newspapers and 
press releases, providing periodic updates on the company website, leveraging social media platforms, and providing 
a dedicated email address for customer queries.
4.	
Does the entity display product information on the product over and above what is mandated as per local laws? 
(Yes/No/ Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to 
consumer satisfaction relating to the major products/ services of the entity, significant locations of operation 
of the entity or the entity as a whole? (Yes/No)
The Company follows the regulations under the Drugs and Cosmetics Act and Rules with respect to product packaging. 
Anti-counterfeit features have also been incorporated on the packaging of some of our products. Other product 
information includes:
•	
QR code (in Divatrone), code numbers (Lycored softgels) and hologram strips on some of the products for verification 
of genuineness of products.
•	
Products contain prescribing information leaflets, for ready reference by the healthcare professional/consumer, as 
per the regulatory requirement
